Press Releases - Archive



Shareholder Tools


 
Press Releases - Archive
Date Title and Summary View
Apr 7, 2010 SAN FRANCISCO, Calif., April 7 , 2010 – Achaogen, a biopharmaceutical company focused on the discovery and development of innovative broad-spectrum antibiotics to treat life-threatening, multi-drug resistant (MDR) bacterial infections, today announced the completion of a $56 million Series C round of financing. The round was ...
Sep 14, 2009 SAN FRANCISCO, CA, September 14, 2009 – Achaogen, a clinical stage biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative, broad-spectrum antibiotics, today announced the results of a Phase 1 trial and preclinical data on its lead drug ca...
Aug 25, 2009 San Francisco, CA, August 25, 2009 – Achaogen, a clinical stage biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative, broad-spectrum antibiotics, announced today the appointment of John C. Doyle to the newly created position of chief op...
Jun 30, 2009 San Francisco, CA, June 30, 2009 – Achaogen, a clinical stage biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative broad-spectrum antibiotics, announced today that it has been selected as one of the annual FierceBiotech “Fierce 15...
May 16, 2009 SAN FRANCISCO, UNITED STATES and HELSINKI, FINLAND, May 16, 2009 – Achaogen, a clinical stage biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative broad-spectrum antibiotics, announced today the presentation of research on aminoglycosid...
Mar 23, 2009 SAN FRANCISCO, CA, March 23, 2009 – Achaogen, a clinical stage biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative broad-spectrum antibiotics, today announced that J. Kevin Judice, Ph.D., chief executive officer and chief scientific of...
Mar 10, 2009 SAN FRANCISCO, CA, March 10, 2009 – Achaogen, a clinical stage biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative broad-spectrum antibiotics, today announced that J. Kevin Judice, Ph.D., chief executive officer and chief scientific of...
Mar 3, 2009 SAN FRANCISCO, CA, March 3, 2009 – Achaogen, a clinical stage biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative broad-spectrum antibiotics, today announced that it has been awarded a contract worth up to $26.6 million over five ye...
Feb 3, 2009 SAN FRANCISCO, CA, February 3, 2009 – Achaogen, an emerging biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative broad-spectrum antibiotics, today announced that it has initiated its first Phase 1 clinical trial. This trial is designed ...
Jan 8, 2009 SAN FRANCISCO, CA, January 8, 2009 – Achaogen, an emerging biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative broad-spectrum antibiotics, today announced that it has received a £4.1 million Seeding Drug Discovery award from ...
Page: FirstPrevious ...
15
NextLast
= add release to Briefcase